Oculis Receives European Medicines Agency PRIME Designation For Privosegtor In Optic Neuritis, Accelerating PIONEER Registrational Program Across Three Global Trials

Oculis has received PRIME designation from the European Medicines Agency for its drug Privosegtor, aimed at treating optic neuritis, following a recent Breakthrough Therapy designation from the U.S. FDA. This designation is supported by positive Phase 2 ACUITY data demonstrating significant vision improvements and neuroprotective benefits. The regulatory momentum enhances Oculis's global development strategy, with the PIONEER registrational program for optic neuropathies in progress, potentially accelerating Privosegtor's regulatory pathway.